Trial Profile
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Therapeutic Use
- 31 Aug 2023 Planned End Date changed from 30 Aug 2023 to 30 Aug 2024.
- 31 Aug 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Aug 2024.
- 06 Jun 2023 Results (n=18; Between 05/2019 and 10/2021) assessing the efficacy and safety of AZD1775 in patients with advanced solid tumor, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.